Influence of CYP2C19 Polymorphism on Lansoprazole and Rabeprazole Maintenance Treatment of Reflux Esophagitis

被引：0
|
作者：
Koike, Tomoyuki
Iijima, Katsunori
Imatani, Akira
Shimosegawa, Tooru
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
W1117
引用
收藏
页码：S655 / S655
页数：1
相关论文
共 50 条
  • [31] Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan
    Miki, I
    Aoyama, N
    Sakai, T
    Shirasaka, D
    Wambura, CM
    Maekawa, S
    Kuroda, K
    Tamura, T
    Kita, T
    Sakaeda, T
    Okumura, K
    Kasuga, M
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (01) : 27 - 33
  • [32] CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Antiplatelet Action of Clopidogrel
    El-Halabi, Mustapha M.
    Zgheib, Nathalie
    Mansour, Nabil M.
    Malli, Ahmad
    Ghaith, Ola A.
    Mahfouz, Rami
    Alam, Samir
    Sharara, Ala I.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2013, 62 (01) : 41 - 49
  • [33] Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism
    Hokari, K
    Sugiyama, T
    Kato, M
    Saito, M
    Miyagishima, T
    Kudo, M
    Nishikawa, K
    Ishizuka, J
    Komatsu, Y
    Mizushima, T
    Kagaya, H
    Hige, S
    Takeda, H
    Asaka, M
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (09) : 1479 - 1484
  • [34] CYP2C19 Polymorphism in Patients with Gastroesophageal Reflux Disease - a Pilot Study
    Poniewierka, Elzbieta
    Neubauer, Katarzyna
    Kempinski, Radoslaw
    Strutynska-Karpinska, Marta
    Sadakierska-Chudy, Anna
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2011, 20 (01): : 65 - 69
  • [35] Comparison of the influence of CYP2C19 polymorphism on the effect of rabeprazole and omeprazole during the early healing phase of gastric ulcer
    Ando, T
    Kato, H
    Kajikawa, H
    Isozaki, Y
    Sugimoto, N
    Seto, N
    Nagao, Y
    Hongo, H
    Furuki, T
    Takamori, S
    Shimozawa, M
    Yoshikawa, T
    GASTROENTEROLOGY, 2002, 122 (04) : A514 - A514
  • [36] The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia
    Rodrigues-Silva, Christielly
    Semedo, Agostinho Tavares
    da Silva Neri, Hiasmin Franciely
    Vianello, Rosana Pereira
    Galaviz-Hernandez, Carlos
    Sosa-Macias, Martha
    de Brito, Rodrigo Bernini
    Ghedini, Paulo Cesar
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 427 - 432
  • [37] Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes
    Miura, M
    Kagaya, H
    Tada, H
    Uno, T
    Yasui-Furukori, N
    Tateishi, T
    Suzuki, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (03) : 315 - 320
  • [38] The key to successful eradication of H. pylori, using lansoprazole or rabeprazole based triple therapy, is clarithromycin resistance, not CYP2C19 polymorphism.
    Miki, I
    Aoyama, N
    Sakai, T
    Shirasaka, D
    Ebara, S
    Wambura, C
    Watanabe, Y
    Kachi, M
    Tamura, T
    Miyamoto, M
    Kasuga, M
    GASTROENTEROLOGY, 2001, 120 (05) : A587 - A587
  • [39] Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: Case of a renal transplant recipient with CYP2C19 gene mutation
    Homma, M
    Itagaki, F
    Yuzawa, K
    Fukao, K
    Kohda, Y
    TRANSPLANTATION, 2002, 73 (02) : 303 - 304
  • [40] A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism
    Hunfeld, N. G.
    Touw, D. J.
    Mathot, R. A.
    van Schaik, R. H.
    Kuipers, E. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (07) : 810 - 818
12345